glp-1 news today november 5 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo GLP-1 Receptor Agonist Market Growth

A supplement brand co-founded by one of the famous Kardashian sisters falsely advertises its Lemme GLP-1 Daily supplement as promoting weight loss, two new class action lawsuits allege

Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Clinical Trials Key Takeaways Retatrutide, a new triple receptor agonist, appears particularly promising as a non-diabetic weight loss agent because it targets glucagon, GLP-1, and GIP

Realworld weightloss effectiveness of glucagonlike peptide1 agonists among patients with type 2 diabetes: A retrospective cohort study

Doria A, Galecki AT, Spino C et al (2020) Serum urate lowering with allopurinol and kidney function in type 1 diabetes

Individuals who have been prescribed Ozempic or other GLP-1 drugs and have subsequently developed severe gastroparesis (stomach paralysis) may be eligible to file an Ozempic Lawsuit and seek compensation

The drug exhibits a dual elimination pathway through both renal and hepatic routes, making it suitable for use in patients with renal impairment